Browse
Submit Data
Databases
API
Help

Dataset Information

5 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-seq of coding and non-coding RNA from miR-522 pulldown in human MDA-MB-468 breast cancer cells

ABSTRACT: Identifying miRNA-regulated genes is key to understanding miRNA function. However, many miRNA recognition elements (MREs) do not follow canonical seed base-pairing rules, making identification of bona fide targets challenging. Here, we apply an unbiased sequencing-based systems approach to characterize miR-522, a member of the oncogenic primate-specific chromosome 19 miRNA cluster, highly expressed in poorly differentiated cancers. To identify miRNA targets, we sequenced full-length transcripts captured by a biotinylated miRNA mimic (this dataset). Within these targets, mostly non-canonical MREs were identified by sequencing RNase-resistant fragments.

ORGANISM(S): Homo sapiens

SUBMITTER: Tan Shen Mynn

PROVIDER: S-ECPF-MTAB-2112 | biostudies-other |

REPOSITORIES: biostudies-other

ACCESS DATA

Json Xml

Similar Datasets

miR-522 IMPACT-seq in MDA-MB-468

Project description: Not available

| S-ECPF-MTAB-2119 | biostudies-other

Transcription profiling of human rapamycin treated of MDA-MB-468 breast cancer cell line and MDA-MB-468 xenografts

Project description: Not available

| S-ECPF-GEOD-18571 | biostudies-other

Overexpressing modified human TR?1 suppresses the proliferation of breast cancer MDA-MB-468 cells.

Project description: Not available

| S-EPMC6019938 | biostudies-literature

Rapamycin treatment of MDA-MB-468 breast cancer cell line and MDA-MB-468 xenografts

Project description:Mammalian target of rapamycin (mTOR) is a serine/threonine kinase involved in multiple intracellular signaling pathways promoting tumor growth. mTOR is aberrantly activated in a significant portion of breast cancers and is a promising target for treatment. Rapamycin and its analogues are in clinical trials for breast cancer treatment. Patterns of gene expression (metagenes) may also be used to simulate a biologic process of effects of a drug treatment. In this study, we tested the hypothesis that the gene-expression signature regulated by rapamycin could predict disease outcome for patients with breast cancer. Results: Colony formation and sulforhodamine B (IC50 < 1nM) assays, and xenograft animals showed that MDA-MB-468 cells were sensitive to treatment with rapamycin. The comparison of in vitro and in vivo gene expression data identified a signature, termed rapamycin metagene index (RMI), of 31 genes upregulated by rapamycin treatment in vitro as well as in vivo (false discovery rate of 10%). In the Miller dataset, RMI was significantly associated with tumor size or lymph node status. High (>75) percentile) RMI was significantly associated with longer survival (P = 0.015). On multivariate analysis, RMI (P = 0.029), tumor size (P = 0.015) and lymph node status (P = 0.01) were prognostic. In van 't Veer study, RMI was not associated with the time to develop distant metastasis (P = 0.41). In Wang dataset, RMI predicted time to disease relapse (P = 0.09). Conclusions: Rapamycin-regulated gene expression signature predicts clinical outcome in breast cancer. This supports the central role of mTOR signaling in breast cancer biology and provides further impetus to pursue mTOR-targeted therapies for breast cancer treatment. Mol Cancer. 2009 Sep 24;8(1):75.

2009-11-20 | GSE18571 | GEO

Selective regain of egfr gene copies in CD44+/CD24-/low breast cancer cellular model MDA-MB-468.

Project description: Not available

| S-EPMC2841141 | biostudies-literature

Long Non-Coding RNA PVT1 Regulates the Resistance of the Breast Cancer Cell Line MDA-MB-231 to Doxorubicin via Nrf2.

Project description: Not available

| S-EPMC7750900 | biostudies-literature

miR-522 Pulldown-seq in MDA-MB-468

Project description:Identifying miRNA-regulated genes is key to understanding miRNA function. However, many miRNA recognition elements (MREs) do not follow canonical seed base-pairing rules, making identification of bona fide targets challenging. Here, we apply an unbiased sequencing-based systems approach to characterize miR-522, a member of the oncogenic primate-specific chromosome 19 miRNA cluster, highly expressed in poorly differentiated cancers. To identify miRNA targets, we sequenced full-length transcripts captured by a biotinylated miRNA mimic (this dataset). Within these targets, mostly non-canonical MREs were identified by sequencing RNase-resistant fragments.

2014-06-03 | E-MTAB-2112 | biostudies-arrayexpress

miR-522 IMPACT-seq in MDA-MB-468

Project description:Identifying miRNA-regulated genes is key to understanding miRNA function. However, many miRNA recognition elements (MREs) do not follow canonical seed base-pairing rules, making identification of bona fide targets challenging. Here, we apply an unbiased sequencing-based systems approach to characterize miR-522, a member of the oncogenic primate-specific chromosome 19 miRNA cluster, highly expressed in poorly differentiated cancers. To identify miRNA targets, we sequenced full-length transcripts captured by a biotinylated miRNA mimic. Within these targets, mostly non-canonical MREs were identified by sequencing RNase-resistant fragments (this dataset).

2014-06-03 | E-MTAB-2119 | biostudies-arrayexpress

Effect of apigenin on whole transcriptome profile of TNF?-activated MDA-MB-468 triple negative breast cancer cells.

Project description: Not available

| S-EPMC7038999 | biostudies-literature

Aryl hydrocarbon receptor (AHR)-active pharmaceuticals are selective AHR modulators in MDA-MB-468 and BT474 breast cancer cells.

Project description: Not available

| S-EPMC3477220 | biostudies-literature